Increased heart rate + 3,4-CTMP
3,4-CTMP is known to produce increased heart rate, a physical effect. A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a forceful, rapid pounding felt throughout the chest, neck, and temples. This effect is among the most commonly reported physiological responses to psychoactive substances and often accompanies stimulation, anxiety, or physical exertion during intoxication.
About Increased heart rate
Increased heart rate, clinically termed tachycardia when exceeding 100 beats per minute at rest, manifests as a heightened awareness of one's own cardiac rhythm. At lower intensities, users may simply notice their pulse feels slightly faster than baseline—a faint thumping sensation in the chest or a mild warmth spreading through the torso. At higher intensities, the heartbeat becomes impossible to ignore: a powerful, rapid drumming that can be felt in the throat, wrists, and behind the eyes, sometimes accompanied by visible pulsation of veins and a sensation of the heart "trying to escape" the ribcage.
The intensity of this effect follows a clear dose-dependent curve. At threshold doses of stimulants or psychedelics, heart rate may increase by only 5-15 BPM above baseline—barely perceptible without deliberately checking one's pulse. At moderate doses, increases of 20-40 BPM become noticeable during both activity and rest, often accompanied by a subtle chest tightness. At high doses or during combinations, heart rate can spike to 140-180+ BPM, producing significant discomfort, breathlessness, and anxiety that may trigger panic responses that further compound the tachycardia.
Several distinct subtypes exist. Stimulant-induced tachycardia tends to feel "electric" and buzzing, as if the heart is running at high RPM but smoothly. Psychedelic tachycardia is often intermittent and closely tied to emotional state—surges of awe or anxiety produce momentary spikes. Cannabinoid-induced increases feel more diffuse and are frequently accompanied by postural hypotension. Dissociative tachycardia is often less consciously noticed due to the analgesic and detaching properties of these substances, making it particularly insidious.
Pharmacologically, increased heart rate results from several mechanisms: direct sympathomimetic activation (as with amphetamines and cocaine, which increase catecholamine release), vagal nerve suppression (as with anticholinergic compounds), peripheral vasodilation triggering baroreceptor-mediated compensatory tachycardia (as with cannabis and some psychedelics), or direct agonism at cardiac beta-adrenergic receptors. Serotonergic compounds can also produce tachycardia via 5-HT2A and 5-HT2B receptor activation.
This effect is most prominently associated with stimulants (amphetamines, cocaine, MDMA, caffeine), but it is also common with psychedelics (LSD, psilocybin, mescaline), cannabinoids (THC), dissociatives (PCP, ketamine at higher doses), and empathogens. Essentially, any substance that activates the sympathetic nervous system or suppresses parasympathetic tone can produce it.
From a harm reduction perspective, increased heart rate becomes dangerous when sustained at very high levels, in individuals with pre-existing cardiac conditions, or when combined with other cardiotoxic substances. The combination of stimulants with MAOIs or other stimulants poses particular risk for hypertensive crisis. Users experiencing tachycardia should avoid further stimulant intake, remain hydrated, practice slow breathing techniques, and seek medical attention if heart rate exceeds 150 BPM at rest or is accompanied by chest pain, irregular rhythm, or difficulty breathing.